AVTX: Avalo Therapeutics, Inc. Stock

by

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 38.85
Enterprise Value ($M) -86.20
Book Value ($M) 122.61
Book Value / Share 11.49
Price / Book 0.32
NCAV ($M) 111.03
NCAV / Share 10.40
Price / NCAV 0.35

Profitability (mra)
Return on Invested Capital (ROIC) 0.59
Return on Assets (ROA) 0.59
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 22.61
Current Ratio 22.61

Balance Sheet (mrq) ($M)
Current Assets 126.94
Assets 138.52
Liabilities 15.91
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.44
Operating Income -40.87
Net Income -35.13
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -49.06
Cash from Investing 0.36
Cash from Financing 175.85

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Biotechnology Value Fund L P 9.99 7.37
12-31 13G Affinity Asset Advisors, LLC 5.30
11-14 13G/A Allostery Investments LP 0.50 -28.64
11-14 13G Orbimed Advisors Llc 9.90
11-07 13G/A Crutcher Patrick J 5.60 395.68
10-07 13G Ikarian Capital, LLC 10.02
08-23 13G Ra Capital Management, L.p. 9.99
2024-04-23 13G Emerald Bioventures, LLC 5.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO
2025-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUAN
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q
2024-07-11 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. 1)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-14 9,413 37,435 25.14
2025-05-13 10,795 32,119 33.61
2025-05-12 11,165 52,483 21.27
2025-05-09 9,023 34,935 25.83

(click for more detail)

Similar Companies
ATNF – 180 Life Sciences Corp. ATOS – Atossa Therapeutics, Inc.
ATYR – aTyr Pharma, Inc. AYTU – Aytu BioPharma, Inc.
BCDA – BioCardia, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.